期刊文献+

100例铜绿假单胞菌致医院获得性肺炎患者30d死亡危险因素分析 被引量:2

Risk factors for 30-day mortality in 100 patients with Paeudomonas Aeruginosa-induced hospital acquired pneumonia
下载PDF
导出
摘要 目的探讨铜绿假单胞菌致医院获得性肺炎30d死亡危险因素,为初始经验性治疗提供参考。方法回顾性调查我院重症监护室2009年1月-2011年10月100例铜绿假单胞菌致医院获得性肺炎患者临床信息,对30d死亡危险因素进行分析,对下呼吸道标本分离的铜绿假单胞菌进行药敏试验。结果高APACHEⅡ评分(P=0.00)和病原菌未覆盖(P=0.01)是医院获得性肺炎30d死亡的危险因素。铜绿假单胞菌对头孢他啶、环丙沙星、头孢吡肟和哌拉西林他唑巴坦耐药率较低,分别为17%、19%、21%和26%。结论高APACHEⅡ评分,病原菌未覆盖是30d死亡危险因素。头孢他啶、环丙沙星、头孢吡肟和哌拉西林他唑巴坦保持着良好的抗铜绿假单胞菌活性。 Objective To provide the reference for initial experience-based treatment of Peudomonas aeruginosa-induced hospital acquired pneumonia(HAP) by studying the risk factors for its 30-day mortality.Methods Clinical data about 100 patients with Paeudomonas aeruginosa-induced HAP admitted to ICU in Chinese PLA General Hospital from January 2009 to October 2011 were retrospectively investigated and risk factors for their 30-day mortality were analyzed.Drug sensitivity test was performed for Paeudomonas aeruginosa isolated from the lower respiratory tract.Results High APACHEⅡscore and uncovered pathogens(P=0.01) were the risk factors for 30-day mortality of HAP patients.The resistance rate of Paeudomonas aeruginosa to ceftazidime,ciprofloxacin,cefepime and piperacillin/tazobactam was very low,accounting for 17%,19%,21% and 26%,respectively.Conclusion High APACHEⅡscore and uncovered pathogens are the risk factors for 30-day mortality of HAP patients.The anti-Paeudomonas aeruginosa activity of ceftazidime,ciprofloxacin,cefepime and piperacillin/tazobactam is rather good.
出处 《军医进修学院学报》 CAS 2012年第6期588-590,共3页 Academic Journal of Pla Postgraduate Medical School
关键词 铜绿假单胞菌 医院获得性肺炎 耐药性 paeudomonas aeruginosa hospital acquired pneumonia resistance
  • 相关文献

参考文献6

二级参考文献21

共引文献36

同被引文献33

  • 1Bruce K, Hicks R. Perioperative pharmacology : a focus on aminoglycosides [ J ] . AORN J, 2011,93 ( 4 ) : 464-468.
  • 2Thong KL, Lai MY, Teh C SJ, et al. Simultaneous detection of methicillin-resistant Staphylococcus aureus, Acinetobacter baumannii, Escherichia coli, Klebsiella pneumoniae and Psendomonas aeruginosa by muhiplex PCR [ J ] . Trop Biomed, 2011, 28 ( 1 ) : 21-31.
  • 3Uslan DZ, Crane SJ, Steckelberg JM, et al. Age- and sex-associated trends in bloodstream infection : a population-based study in Olmsted County, Minnesota [ J ] . Arch Intern Med, 2007, 167 ( 8 ) : 834- 839.
  • 4Mar t n M, Gudiol C, Garcia-Vidal C, et al. Bloodstream infections in patients with solid tumors : epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center [ J ]. Medicine ( Baltimore ) , 2014, 93 ( 3 ) : 143-149.
  • 5Hirsch EB, Cottreau JM, Chang KT, et al. A model to predict mortality following Pseudomonas aeruginosa haeteremia [ J ] . Diagn Microbiol Infect Dis, 2012, 72 ( 1 ) : 97-102.
  • 6Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa baeteremia : risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome [ J ] . Clin Infect Dis, 2003, 37 ( 6 ) : 745-751.
  • 7Willmann M, Kuebart I, Vogel W, et al. Time to positivity as prognostic tool in patients with Pseudomonas aeruginosa bloodstream infection [ J ]. J Infect, 2013, 67 ( 5 ) : 416-423.
  • 8Su TY, Ye JJ, Hsu PC, et al. Clinical characteristics and risk factors for mortality in cefepime-resistant Pseudomonas aeruginosa bacteremia [ J ] . J Microbiol Immunol Infect, 2015, 48 ( 2 ) : 175- 182.
  • 9Parkins MD, Gregson DB, Pitout JD, et al. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection [ J ] . Infection, 2010, 38 ( 1 ) : 25-32.
  • 10Morata L, Cobos-Trigueros N, Mart e nez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30- day mortality rate of Pseudomonas aeruginosa bacteremia [ J ] . Antimicrob Agents Chemother, 2012, 56 ( 9 ) : 4833-4837.

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部